Novo Nordisk is the latest big pharma to get in on the NLRP3 action, paying $70 million upfront for the exclusive license for Ventus' VENT-01 program.

It also puts Novo Nordisk in competition with others that are developing NLRP3-blocking drugs. Roche entered the space through its 2018 acquisition of Jecure Therapeutics .

Novo Nordisk announced Thursday that it has entered an exclusive development and license agreement for $70 million with Ventus Therapeutics for its NLRP3 inhibitor program.. As part of the transaction ...

Biotechnology startup Ventus Therapeutics is licensing its lead research program, a drug candidate for inflammatory disorders, to Novo Nordisk A/S (NYSE: NVO) for an upfront $70 million. The lead ...

In exchange, Novo Nordisk will receive exclusive worldwide rights to develop and commercialize Ventus’ lead NLRP3 inhibitor program for a broad range of diseases, including nonalcoholic ...

In May 2024, Novo Nordisk successfully dosed the first participant in a Phase I clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in ...

After two years of talks, privately held Ventus Therapeutics Inc. and Novo Nordisk A/S have signed an exclusive worldwide license deal to commercialize candidates from Ventus’ portfolio of ...

NodThera’s NLRP3 inhibitor has already proved its worth against Novo Nordisk’s blockbuster obesity drug in preclinical trials. Now, an early readout from a study in humans with obesity has ...

An inflammasome known as NLRP3 is the focus of Ventus' experimental treatment. NLRP3 is implicated in many diseases, including Alzhe Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus' Lead ...

After two years of talks, privately held Ventus Therapeutics Inc. and Novo Nordisk A/S have signed an exclusive worldwide license deal to commercialize candidates from Ventus’ portfolio of ...